From the latest CLL Tidbits Newsletter from the CLL Global Research Foundation: "CLL has a profound effect on patients' quality of life because of a number of disease-related symptoms among which fatigue is perhaps the best recognized.
:
Dr. Estrov and his team discovered that stimulation of CLL cells results in activation of a factor termed Janus kinase (JAK)-2 and the drug ruxolitinib (Jakafi) inhibits this effect.
:
To test whether ruxolitinib would alleviate the symptoms of patients with CLL that otherwise do not require anti-leukemia therapy, Dr. Estrov initiated a small clinical trial. With the support of Incyte Corporation, the drug's manufacturer, ruxolitinib has been administered to CLL patients. In the vast majority of the 30 patients that were enrolled onto the study thus far, ruxolitinib significantly reduced CLL-related symptoms and improved the patients' quality of life."
You can read previous issues of Tidbits here:
archive.constantcontact.com...
If you'd like to receive Tidbits emails from the CLL Global Research Foundation, you can sign up here:
visitor.r20.constantcontact...
Neil
Photo: Banksia flower and seeds. This distinctive plant genus is named after Sir Joseph Banks, the botanist that accompanied Captain James Cook on his first great exploration of the South Pacific, including much of the East coast of Australia on the H.M.S. Endeavour (1768–1771).
CLL INFORMATION - A developing reliable and current international list of CLL Information & Resources.
ASH 2018: Dr. Chadi Nabhan on the Cost of Ibrutinib vs. Chemo vs Chemoimmunotherapy in CLL and on way too much chemo being used.
Scientists hail autoimmune disease therapy breakthrough - implications for CLL patients?
